Propylallyltryptamine
Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).
The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 6 receptors, but not of the serotonin 5-HT 1A receptor. It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). The chemical synthesis of PALT has been described.
A notable analogue of PALT is iPALT (ASR-3003). PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.
See also
Substituted tryptamine
Text derived from https://en.wikipedia.org/w/index.php?oldid=1360364400 under CC BY-SA 4.0; modifications have been made.